INTRODUCTION: The Cancer and Leukemia Group B (CALGB) conducted a multi-center phase II trial to evaluate the efficacy and safety of vatalanib in previously untreated patients with malignant mesothelioma and to evaluate potential biomarkers of disease response (CALGB 30107). METHODS: Treatment consisted of vatalanib 1250 mg given orally once daily. CT scans were obtained at baseline and every 6 weeks thereafter. Baseline serum levels of vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), thrombospondin-1 (TSP-1), and mesothelin were obtained. The primary endpoint was 3-month progression-free survival (PFS). RESULTS: Forty-seven patients enrolled at 19 centers. The median age was 75 years, and the majority of patients (79%) had an ECOG performance status of 1. Tumors were classified as epithelial (77%), sarcomatoid (10%), or mixed (9%) histology. Toxicity was mild; the most common grade 3/4 adverse events were neutropenia (2%), nausea (15%), elevated alanine aminotransferase (11%), hypertension (2%), and gastrointestinal bleeding (2%). Partial responses were observed in 6% of patients and stable disease in 72% of patients. The 3-month PFS rate was 55% (95% CI: 40%, 68%). The median PFS was 4.1 months. Median overall survival was 10.0 months. There was no correlation between serum levels of VEGF, PDGF, TSP-1, or mesothelin and treatment response, PFS, or survival. CONCLUSIONS: Vatalanib as a single agent with this dose and schedule does not warrant further study in this disease.
INTRODUCTION: The Cancer and Leukemia Group B (CALGB) conducted a multi-center phase II trial to evaluate the efficacy and safety of vatalanib in previously untreated patients with malignant mesothelioma and to evaluate potential biomarkers of disease response (CALGB 30107). METHODS: Treatment consisted of vatalanib 1250 mg given orally once daily. CT scans were obtained at baseline and every 6 weeks thereafter. Baseline serum levels of vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), thrombospondin-1 (TSP-1), and mesothelin were obtained. The primary endpoint was 3-month progression-free survival (PFS). RESULTS: Forty-seven patients enrolled at 19 centers. The median age was 75 years, and the majority of patients (79%) had an ECOG performance status of 1. Tumors were classified as epithelial (77%), sarcomatoid (10%), or mixed (9%) histology. Toxicity was mild; the most common grade 3/4 adverse events were neutropenia (2%), nausea (15%), elevated alanine aminotransferase (11%), hypertension (2%), and gastrointestinal bleeding (2%). Partial responses were observed in 6% of patients and stable disease in 72% of patients. The 3-month PFS rate was 55% (95% CI: 40%, 68%). The median PFS was 4.1 months. Median overall survival was 10.0 months. There was no correlation between serum levels of VEGF, PDGF, TSP-1, or mesothelin and treatment response, PFS, or survival. CONCLUSIONS:Vatalanib as a single agent with this dose and schedule does not warrant further study in this disease.
Authors: L Strizzi; A Catalano; G Vianale; S Orecchia; A Casalini; G Tassi; R Puntoni; L Mutti; A Procopio Journal: J Pathol Date: 2001-04 Impact factor: 7.996
Authors: J M Wood; G Bold; E Buchdunger; R Cozens; S Ferrari; J Frei; F Hofmann; J Mestan; H Mett; T O'Reilly; E Persohn; J Rösel; C Schnell; D Stover; A Theuer; H Towbin; F Wenger; K Woods-Cook; A Menrad; G Siemeister; M Schirner; K H Thierauch; M R Schneider; J Drevs; G Martiny-Baron; F Totzke Journal: Cancer Res Date: 2000-04-15 Impact factor: 12.701
Authors: Pankaj Gupta; Flora Mulkey; Robert P Hasserjian; Ben L Sanford; Ravi Vij; David D Hurd; Olatoyosi M Odenike; Clara D Bloomfield; Kouros Owzar; Richard M Stone; Richard A Larson Journal: Invest New Drugs Date: 2013-05-23 Impact factor: 3.850
Authors: Nicholas P Campbell; Rangesh Kunnavakkam; Natasha Leighl; Mark D Vincent; David R Gandara; Marianna Koczywas; Barbara J Gitlitz; Edem Agamah; Sachdev P Thomas; Walter M Stadler; Everett E Vokes; Hedy L Kindler Journal: Lung Cancer Date: 2012-07-23 Impact factor: 5.705